X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
1. 3-(2,4-dimethylpyrrol-5-yl)methylidene-indolin-2-one
2. Semaxinib
3. Su 5416
4. Su-5416
5. Su5416
6. Sugen 5416
1. Semaxinib
2. Su5416
3. 204005-46-9
4. Su 5416
5. 194413-58-6
6. Su-5416
7. Semoxind
8. Semaxanib (su5416)
9. Tsu 16
10. Z-semaxanib
11. Nsc-696819
12. Vegfr2 Kinase Inhibitor Iii
13. (z)-3-((3,5-dimethyl-1h-pyrrol-2-yl)methylene)indolin-2-one
14. (3z)-3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-1h-indol-2-one
15. (z)-su 5416
16. 71ia9s35aj
17. Chembl276711
18. (3z)-3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-1,3-dihydro-2h-indol-2-one
19. 3-(1-(3,5-dimethyl-1h-pyrrol-2-yl)meth-(z)-ylidene)-2-oxo-2,3-dihydroindole
20. 3-((z)-(3,5-dimethylpyrrol-2-yl)methylene)-2-indolinone
21. Su005416
22. Semaxnib
23. Sugen 5416
24. 3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-1,3-dihydro-2h-indol-2-one
25. (3z)-3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-2,3-dihydro-1h-indol-2-one
26. Semaxanib [inn]
27. Semaxanib(su5416)
28. Smr000568416
29. Vegf Receptor 2 Kinase Inhibitor Iii
30. Tsu-16
31. Sr-01000076044
32. Semaxanib (usan/inn)
33. Semaxanib [usan:inn]
34. Methylene]-2h-indol-2-one
35. Unii-71ia9s35aj
36. (3z)-3-((3,5-dimethyl-1h-pyrrol-2-yl)methylidene)-1,3-dihydro-2h-indol-2-one
37. (z)-semaxanib
38. (z)-semaxinib
39. Ncgc00094381-03
40. 3-(2,4-dimethylpyrrol-5-yl)methylidene-indolin-2-one
41. Nsc 696819
42. 2x2m
43. Semaxanib; Su5416
44. Semaxanib [usan]
45. Semaxanib [mart.]
46. H-indol-2-one, 3-((3,5-dimethyl-1h-pyrrol-2-yl)methylene)-1,3-dihydro-
47. S 8442
48. Schembl8190
49. Semaxanib [who-dd]
50. Lopac0_001110
51. Schembl19571
52. 1,3-dihydro-3-[(3,5-dimethyl-1h-pyrrol-2-yl)
53. Mls001074896
54. Mls001332519
55. Mls001332520
56. Bdbm4810
57. Gtpl5056
58. 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]indolin-2-one
59. Chebi:91083
60. Cid_5329098
61. 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-indolin-2-one
62. Bdbm497339
63. Dtxsid801025708
64. Hms2234l12
65. Hms3229o13
66. Hms3263m22
67. Hms3268j13
68. Hms3413h10
69. Hms3648o12
70. Hms3677h10
71. (3z)-3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylene]indolin-2-one
72. Amy10847
73. Bcp06068
74. Ex-a2158
75. Tox21 111271
76. Tox21_501110
77. Hsci1_000303
78. Mfcd09763655
79. Nsc696819
80. S2845
81. Su5146
82. Zinc12410091
83. Akos015994557
84. Ccg-205186
85. Cs-1225
86. Db06436
87. Es-0010
88. Lp01110
89. Sdccgsbi-0051079.p003
90. Us11001595, Compound Su5416
91. Ncgc00094381-01
92. Ncgc00094381-02
93. Ncgc00094381-04
94. Ncgc00094381-05
95. Ncgc00094381-19
96. Ncgc00261795-01
97. Ac-35250
98. Hy-10374
99. Eu-0101110
100. Sw219791-1
101. D05819
102. N11132
103. A857052
104. A899499
105. 2h-indol-2-one,5-dimethyl-2-pyrrolyl)methylene]-
106. J-013281
107. Q7449140
108. Sr-01000076044-2
109. Sr-01000076044-8
110. Brd-k63504947-001-05-5
111. 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinon
112. 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone
113. 3-((3,5-dimethyl-1h-pyrrol-2-yl)methylene)indolin-2-one
114. Semaxanib, Semoxind, Tsu-16, Nsc-696819, Su-5416
115. 3-[(3,5-dimethyl-2h-pyrrol-2-ylidene)methyl]-1h-indol-2-ol
116. 3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylene]-1,3-dihydro- 2h-indol-2-one
117. 3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylene]-1,3-dihydro-2h-indol-2-one
118. (3z)-3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylene]-1,3-dihydro-2h-indol-2-one
119. 2h-indol-2-one, 3-((3,5-dimethyl-1h-pyrrol-2-yl)methylene)-1,3-dihydro-, (3z)-
120. 2h-indol-2-one, 3-((3,5-dimethyl-1h-pyrrol-2-yl)methylene)-1,3-dihydro-, (z)-
121. 2h-indol-2-one, 3-(3,5-dimethyl-1h-pyrrol-2-yl)methylene)- 1,3-dihydro-, (z)-
122. 2h-indol-2-one, 3-(3,5-dimethyl-1h-pyrrol-2-yl)methylene)- 1,3-dihydro-,(z)-
123. 2h-indol-2-one,3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylene]-1,3-dihydro-, (3z)-
124. 3-[1-(3,5-dimethyl-1h-pyrrol-2-yl)-meth-(z)-ylidene]-2-oxo-2,3-dihydro-indole
| Molecular Weight | 238.28 g/mol |
|---|---|
| Molecular Formula | C15H14N2O |
| XLogP3 | 2.5 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 1 |
| Rotatable Bond Count | 1 |
| Exact Mass | 238.110613074 g/mol |
| Monoisotopic Mass | 238.110613074 g/mol |
| Topological Polar Surface Area | 44.9 Ų |
| Heavy Atom Count | 18 |
| Formal Charge | 0 |
| Complexity | 377 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in colorectal cancer and lung cancer.
Angiogenesis Inhibitors
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels. (See all compounds classified as Angiogenesis Inhibitors.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
Market Place
